GlassScriptPhysician profile
Katherine Toma
NPI 1508257395
$3,485.30
in general payments reported to CMS, 2019-2025
26 companies · $1,120 in 2025
The $1,120 reported for 2025 was more than what 80% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $180 · 2022: $389 · 2023: $877 · 2024: $920 · 2025: $1,120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,900 · Education: $16.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,900.28 |
| Education | $16.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $947.96 | 2021-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $389.98 | 2022-2025 | Jynarque, Voyxact |
| Amgen INC. | $314.30 | 2023-2025 | Krystexxa, Tavneos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $274.64 | 2022-2025 | Jardiance |
| Travere Therapeutics, INC. | $195.49 | 2023-2025 | Filspari |
| Glaxosmithkline, LLC. | $188.20 | 2022-2025 | Benlysta, Jesduvroq |
| Novartis Pharmaceuticals Corporation | $159.45 | 2024-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $147.65 | 2023-2025 | Jynarque, Voyxact |
| Fresenius USA Marketing, INC. | $133.29 | 2021-2024 | Velphoro |
| Calliditas Therapeutics US INC. | $106.12 | 2024-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $92.85 | 2022-2025 | |
| Daiichi Sankyo INC. | $85.48 | 2022-2024 | Injectafer |
| Novo Nordisk INC | $74.71 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Aurinia Pharma U.S., INC. | $50.03 | 2023-2025 | Lupkynis |
| Esperion Therapeutics, INC. | $49.76 | 2021-2023 | Nexletol |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $45.62 | 2023-2025 | Jardiance, Mounjaro |
| Vifor Pharma, INC. | $44.25 | 2021-2025 | Veltassa |
| Scpharmaceuticals INC. | $34.70 | 2025 | |
| Ardelyx, INC. | $32.51 | 2024-2025 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $27.56 | 2024-2025 | Terlivaz |
| Renalytix Ai, INC. | $20.04 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Ani Pharmaceuticals, INC. | $15.85 | 2023 | Purified Cortrophin Gel |
| Corcept Therapeutics | $14.13 | 2023 | Korlym |
| Horizon Therapeutics Plc | $13.71 | 2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $13.61 | 2022 | |
| Akebia Therapeutics INC | $13.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Toma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.